Treprostinil

Last updated on: 25.08.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Treprostinil is a stable tricyclic analog of prostacyclin3 that promotes vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation (Feldman J et al 2020). It relieves symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (Feldman J et al 2020).

Pharmacodynamics (Effect)This section has been translated automatically.

Treprostinil is a stable analog of prostacyclin, a prostaglandin that acts as an antithrombotic agent and potent vasodilator. Prostacyclin analogs are useful in the treatment of pulmonary arterial hypertension (PAH), a disease characterized by abnormally high blood pressure in the arteries between the heart and lungs (Ding M et al 2021). PAH leads to right heart failure due to remodeling of the pulmonary arteries, and patients with this disease have a poor prognosis (Feldman J et al 2020).

Treprostinil binds and activates the prostacyclin receptor, prostaglandin D2 receptor 1, and prostaglandin E2 receptor 2.3 Activation of these receptors leads to an increase in intracellular cyclic adenosine monophosphate (cAMP), which subsequently promotes the opening of calcium-activated potassium channels leading to cell hyperpolarization (Ding M et al. 2021).3 This mechanism promotes direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation (Del Pozo R etal. 2017). In addition to its direct vasodilatory effect, treprostinil also inhibits inflammatory processes (Ding M et al. 2021).

Spectrum of actionThis section has been translated automatically.

As an analog of prostacyclin, treprostinil promotes vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

IndicationThis section has been translated automatically.

Through the FDA, treprostinil has been approved for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise capacity. It is also used to treat pulmonary arterial hypertension in patients who need to be switched from epoprostenol.

Undesirable effectsThis section has been translated automatically.

Because of its ability to inhibit platelet aggregation, treprostinil may increase the risk of bleeding, and patients with low systemic arterial pressure taking treprostinil may experience symptomatic hypotension. Abrupt discontinuation of treprostinil or drastic dose changes may exacerbate symptoms of pulmonary arterial hypertension (PAH). Inhalation of treprostinil may also cause bronchospasm in patients with asthma, chronic obstructive pulmonary disease (COPD), or bronchial hyperresponsiveness.5 When administered intravenously, treprostinil may cause infusion complications and increase the risk of bloodstream infections.

Note(s)This section has been translated automatically.

Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following dosage forms: subcutaneous, intravenous, inhaled, and oral. The first generic form of treprostinil became available in 2019 (Feldman J et al 2020).

LiteratureThis section has been translated automatically.

  1. Del Pozo R etal. (2017) The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med 11:491-503.
  2. Ding M et al (2021) Treprostinil, a prostacyclin analog, ameliorates renal ischemia-reperfusion injury: preclinical studies in a rat model of acute kidney injury. Nephrol Dial Transplant 36:257-266.
  3. Lindegaard Pedersen M et al (2019) The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol. 2019 Aug 12. doi: 10.1111/bcpt.13305. [Article.]
  4. Feldman J et al (2020) Treprostinil in the treatment of pulmonary arterial hypertension. Future Cardiol 16:547-558.

Last updated on: 25.08.2023